Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20507 studies found for:    research medical center
Show Display Options
Rank Status Study
1 Completed A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Biological: Stem cells;   Other: Placebo
2 Completed Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Condition: Ocular Infections, Irritations and Inflammations
Interventions: Drug: KPI-121;   Drug: Vehicle of KPI-121 Ophthalmic Suspension
3 Completed Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121;   Drug: Placebo
4 Completed Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Condition: Blepharitis
Interventions: Drug: KPI-121;   Drug: Vehicle
5 Completed Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: P-321 Ophthalmic Solution;   Drug: P-321 Ophthalmic Solution placebo
6 Completed Efficacy of Dead Sea Peloid Gel in Chronic Endometritis
Condition: Chronic Endometritis
Intervention: Drug: Dead Sea Peloid Gel
7 Active, not recruiting A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: pegfilgrastim
8 Terminated
Has Results
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
Conditions: Heart Failure;   Ventricular Dyssynchrony
Intervention: Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
9 Completed The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)
Condition: Blepharitis
Interventions: Drug: Azithromycin ophthalmic solution, 1%;   Drug: Placebo
10 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
11 Completed TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program
Condition: Coronary Artery Disease
Intervention: Device: TAXUS Express 2™
12 Active, not recruiting
Has Results
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Concurrent temozolomide;   Radiation: Concurrent radiation therapy;   Drug: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;   Drug: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
13 Completed SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
14 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
15 Active, not recruiting Active Bathing to Eliminate Infection (ABATE Infection) Trial
Conditions: Healthcare Associated Infections;   Methicillin Resistant Staphylococcus Aureus;   Multi Drug Resistant Organisms
Intervention: Drug: Arm 2: Decolonization
16 Completed SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
17 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
18 Completed
Has Results
Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
Conditions: Diabetic Retinopathy;   Diabetic Macular Edema
Interventions: Drug: Triamcinolone Acetonide + laser;   Drug: Ranibizumab + laser;   Drug: Sham injection + laser;   Drug: Ranibizumab + deferred laser
19 Active, not recruiting Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Cognitive Side Effects of Cancer Therapy;   Malignant Ovarian Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Choriocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Dysgerminoma;   Ovarian Embryonal Carcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Germ Cell Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Polyembryoma;   Ovarian Sarcoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Teratoma;   Ovarian Yolk Sac Tumor;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
20 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years